AT IMPF
AT IMPF
Founded:
2010-01-01
Status:
Active
Similar Organizations
Edbru AG
Edbru AG was added in 2014.
Gemeente Delft
Gemeente Delft is over 750 years old, the city owes its name to the 'digging' of the oldest canal, the Oude Delft.
Growth Tech Ventures, Inc
Growth Tech Ventures, Inc was added in 2013.
SS Capital
SS Capital was added in 2010.
VIR
VIR was added in 2013.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-03-17 | immatics biotechnologies | AT Impf investment in Post-IPO Equity - immatics biotechnologies | 104 M USD |
| 2017-10-04 | immatics biotechnologies | AT Impf investment in Series E - immatics biotechnologies | 58 M USD |
| 2014-07-16 | immatics biotechnologies | AT Impf investment in Series D - immatics biotechnologies | 22 M EUR |
| 2014-01-07 | Isarna Therapeutics | AT Impf investment in Venture Round - Isarna Therapeutics | 17.8 M USD |
| 2013-10-15 | immatics biotechnologies | AT Impf investment in Series D - immatics biotechnologies | 12 M EUR |
| 2010-09-21 | immatics biotechnologies | AT Impf investment in Series C - immatics biotechnologies | 54 M EUR |
More informations about "AT Impf"
AT Impf - Crunchbase Investor Profile & Investments
Immatics biotechnologies raised €22,000,000 / Series D from AT Impf and 2 other investors . Discover more funding rounds . View All . Details. Edit Details Section. Headquarters Regions European Union (EU), Europe, Middle East, and Africa (EMEA) Founded Date 2010; …See details»
AT Impf - Investments, Portfolio & Company Exits - Crunchbase
Mar 17, 2020 AT Impf has made 6 investments. Their most recent investment was on Mar 17, 2020, when immatics biotechnologies raised. obfuscated. obfuscated. AT Impf has had . …See details»
AT Impf investment portfolio - PitchBook
AT Impf's latest investment was on 04-Oct-2017 in Immatics, a company within the Biotechnology industry. Data Transparency. Meet our data hygiene team. Discover how our experts ensure …See details»
SEC.gov | HOME
ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of our ordinary shares. Entities controlled by ATHOS KG mainly provide …See details»
AT Impf GmbH Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for AT Impf GmbH of München, Bayern. Get the latest business insights from Dun & Bradstreet.See details»
SC 13G - SEC.gov
This Schedule 13G is being jointly filed by ATHOS KG, AT Impf GmbH, Helmut Jeggle and Thomas Maier, each of the foregoing, a “Reporting Person,” and collectively, the “Reporting …See details»
EXCLUSIVE: The Single Family Office Behind World’s First …
Nov 10, 2020 Athos Service holds 50.33 per cent of BioNTech through an investment vehicle named AT Impf GmbH. BioNTech was listed on Nasdaq with a market cap on 9 November at …See details»
Die Deals der deutschen Biotechinvestoren
Heute sind sie über die AT Impf, die ebenfalls wie die Athos Service ihren Sitz in München hat, der größte Anteilseigner des Mainzer Unternehmens. Dietmar Hopp: Portfolioaufbau ab 2005. Dietmar Hopp ist mit seinen Beteiligungen …See details»
AT Impf - Golden
AT Impf A venture capital firm in Munich, Germany that invests in the biotechnology and pharmaceutical sectors Overview Structured Data Issues Contributors ActivitySee details»
AT Impf - Crunchbase
AT Impf was added in 2010.See details»
What Is The Ownership Structure Like For BioNTech SE …
May 16, 2022 AT Impf GmbH is currently the largest shareholder, with 44% of shares outstanding. For context, the second largest shareholder holds about 17% of the shares …See details»
‘Biotech is the ultimate impact investment’ — family offices can’t …
They own 43.5 per cent of BioNTech through an investment vehicle called AT Impf, according to a recent SEC filing, making their stake worth around $14bn. “It’s a great example of the capacity ...See details»
SEC.gov | HOME
AT Impf GmbH, Munich, Germany is the parent company of the Group and owned the following percentage of ordinary shares in BioNTech at the following dates as indicated: Ownership of …See details»
At Impf GmbH - BioCentury Company Profiles - BCIQ
Sep 27, 2010 At Impf GmbH - BioCentury Company Profiles for the biopharma industrySee details»
AT Impf GmbH - Implisense
Nov 1, 2024 Das Eigenkapital der AT Impf GmbH hat sich um % verglichen mit dem Vorjahreswert auf Euro und das Anlagevermögen um % auf Euro maßgeblich erhöht. Diese …See details»
immatics Raises EUR54 Million to Advance its Late Stage Clinical ...
Sep 21, 2010 AT Impf GmbH is a wholly owned company of Dr. Andreas and Dr. Thomas Strungmann. The company holds several Biotech-Investments and is managed by the Family …See details»
AT Impf Portfolio Investments, AT Impf Funds, AT Impf Exits - CB …
Nov 1, 2017 AT Impf is a wholly owned company of Dr. Andreas and Dr. Thomas Strungmann. The company holds several Biotech-Investments and is managed by the Family Office of the …See details»
Meet Twin Brother Billionaires Behind BioNTech’s Success
Feb 8, 2022 These investments lead to AT Impf being the controlling shareholder at the time of the IPO at Nasdaq on October 10th, 2019, owning 50,2% of the company. The MIG Fonds …See details»
SC 13G/A - SEC.gov
Feb 14, 2023 This Amendment No. 3 to Schedule 13G is being jointly filed by ATHOS KG, AT Impf GmbH and Thomas Maier, each of the foregoing, a “Reporting Person,” and collectively, …See details»
There are daily pills to prevent HIV — but injectable options could ...
3 days ago The long-acting injectable drug for PrEP, cabotegravir, sold under the brand name Apretude, was approved by Health Canada in 2024 to reduce the risk of sexually acquired HIV.See details»